Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
Holding TXG?
Track your performance easily
Earnings Data
Report Date
Feb 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.3Last Year’s EPS
-0.41Same Quarter Last Year
Moderate Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2020
|% Change Since: -4.50%
|Next Earnings Date:Nov 07, 2019
Earnings Call Sentiment|Negative
While the company made strides in improving gross margins and saw significant growth in spatial consumables, it faced challenges with declining overall revenue, sales restructuring disruptions, and cautious customer spending. The sentiment is tempered by the strong spatial consumables performance but overshadowed by the revenue decline and sales restructuring issues.Company Guidance
During the third quarter 2024 earnings call for 10x Genomics, the company provided updated financial guidance alongside various metrics. Serge Saxonov, the CEO, reported that quarterly revenue decreased by 1% year-over-year, with full-year revenue now expected to range between $595 million to $605 million, signifying a 3% decline compared to the prior year. The guidance assumes a flat fourth quarter revenue compared to the third quarter. The company faced headwinds from a major sales restructuring and cautious customer spending due to a challenging macroeconomic environment. The restructuring led to significant changes, including a specialized capital equipment team and recalibrated territories, impacting over 40% of customer accounts in the Americas. Despite these challenges, 10x Genomics is focused on initiatives to drive growth, including evolving its commercial structure, creating accessible price points, and advancing product capabilities, all while maintaining a disciplined approach to cash management.Spatial Consumables Revenue Growth
Spatial consumables revenue increased by 111%, driven by demand for new products like Visium HD and Xenium 5K.
Strong Gross Margin Improvement
Gross margin increased to 70% from 62% the previous year, driven by a change in product mix with fewer Xenium instruments.
Chromium Portfolio Pricing Strategy
New products like GEM-X Flex and Universal Multiplex were launched to lower costs, with GEM-X Flex reducing the cost per cell by over fivefold.
---
TXG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
TXG Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 29, 2024 | $15.79 | $16.49 | +4.43% |
| Aug 08, 2024 | $19.55 | $20.43 | +4.50% |
| Apr 30, 2024 | $29.28 | $26.92 | -8.06% |
| Feb 15, 2024 | $48.07 | $48.45 | +0.79% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does 10x Genomics Inc (TXG) report earnings?
10x Genomics Inc (TXG) is schdueled to report earning on Feb 12, 2025, TBA Not Confirmed.
What is 10x Genomics Inc (TXG) earnings time?
10x Genomics Inc (TXG) earnings time is at Feb 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TXG EPS forecast?
TXG EPS forecast for the fiscal quarter 2024 (Q4) is -0.3.
---